Avalo Therapeutics (AVTX) director acquires 3,166 shares via RSU vesting

robot
Abstract generation in progress

Avalo Therapeutics director Samantha Truex acquired 3,166 shares of common stock through the vesting and exercise of restricted stock units (RSUs). This transaction, which occurred on March 28, 2026, increased her direct common stock holdings to 6,333 shares. The RSUs were part of a larger grant from August 2024, vesting in three equal installments contingent on her continued service.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin